Suprainguinal Fascia Iliaca Compartment Block in Direct Anterior Approach to Total Hip Arthroplasty
NCT ID: NCT05237479
Last Updated: 2022-10-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
NA
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-30
Study Completion Date
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this study is to determine whether or not a suprainguinal fascia iliaca compartment nerve block is effective at improving postoperative pain control in patients receiving an anterior approach hip replacement surgery. In general, postoperative pain control has a significant impact on earlier ambulation, initiation of physical therapy, better functional recovery, and overall patient satisfaction. The hypothesis is that providing patients with this nerve block will decrease opioid requirements in patients undergoing this surgery as compared to patients that do not receive the block.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analgesic Comparison of PENG/LFCN to FICB for Total Hip Arthroplasty
NCT05477641
Analgesia
UNKNOWN
NA
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
NCT04690647
Anesthesia, Local
Analgesia
Arthropathy of Hip
COMPLETED
NA
Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty
NCT01758497
Pain Disorder
Sensory Deficit
COMPLETED
NA
Pericapsular Nerve Group (PENG) Block Versus Supra-inguinal Fascia Iliaca Compartment Block for Pain Management After Total Hip Arthroplasty: a Randomized Controlled Trial
NCT04426045
Total Hip Arthroplasty
Postoperative Pain
COMPLETED
NA
Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty
NCT02933671
Hip Osteoarthritis
Primary Total Hip Arthroplasty
Pain
TERMINATED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design: Interventional Trial
Allocation: Randomized
Intervention Model: Parallel Assignment
Treatment groups: Group A: Control Group - DAA THA under spinal anesthesia ( standard of care at Montefiore)
Group B: Intervention Group - DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
Blinding Procedures:
* On the day of surgery, a sealed envelope with group allocation (Group A- Control vs. Group B - Intervention) will be opened by a team member not involved with data collection.
* For patients allocated to Group B - Intervention: A regional anesthesia block team consisting of a regional anesthesiologist, regional fellow, and resident will carry out the S-FICB in the preoperative area prior to surgery
* A separate anesthesia team consisting of an anesthesiologist and certified nurse anesthetist will be responsible for the spinal anesthetic and monitored anesthesia care for both groups in the operating room
* A separate acute pain service team will follow the patients in both groups on postoperative day 1 and evaluate sensory and motor distribution of LFCN, FN, and ON for both groups
* A research assistant blinded to the allocation of both groups will collect data from the EMR for analysis. In addition, a research assistant blinded to the allocation of both groups will call patients via telephone 24 hours post-discharge for a patient satisfaction survey.
Hypothesis: The supra-inguinal fascia iliaca compartment block will decrease 24 hours post-surgery opioid requirements in patients undergoing elective direct anterior approach to total hip arthroplasty.
Target Population: Patients undergoing primary elective total hip arthroplasty under direct anterior surgical approach
Recruitment methods: Participants who meet the inclusion/exclusion criteria for the study will be approached to participate in the study at the preoperative visit at the Orthopedic Surgeon's Office. Informed consent for participation in the study will be obtained during the preoperative visit.
The planned interventions and their timing:
* On the day of surgery, patients who have been randomized to Group B - Intervention will receive a preoperative S-FICB using 35 ml of 0.5% ropivacaine (max dose of 3mg/kg) under ultrasound guidance by the regional anesthesia block team once the patient has been marked by the surgeon
* The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. For those patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory and motor distribution of LFCN, FN, and ON will be assessed by the regional anesthesia block team prior to going to the operating room.
* All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory and motor distribution of LFCN, FN, and ON and adjustment of pain medication regimens
* All patients will receive a telephone call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
* Postoperatively all patients will be placed on the following pain regimen:
* All patients will be started on a Hydromorphone intravenous patient-controlled analgesia (PCA) for 24 hours, with starting parameters: 0.2mg q10 min bolus dosing without a basal rate.
* A standardized regimen of non-opioid adjuvants will include: Acetaminophen 975mg po q8h, Pregabalin 50mg po BID, Ketorolac 15mg q8h IV x 24 hours followed by Celebrex 200mg po BID.
* After the first 24 hours, patients will be transitioned off the hydromorphone PCA with oxycodone 5mg PO q4h prn for moderate pain and 10mg PO q4h prn for severe pain, hydromorphone 0.2mg IV q4h prn for breakthrough pain. These doses may be increased or decreased thereafter at the discretion of the acute pain service team based on patient evaluation and reported pain scores.
Study Population
A. Patients undergoing elective primary total hip arthroplasty under direct anterior surgical approach with neuraxial anesthesia
Participant Recruitment
Participants will be recruited during their preoperative visit to the office of the orthopedic surgery team performing the patient's surgery. At this visit, where the patient will be consented for the surgery itself, the orthopedic surgery team will present the opportunity to participate in this study during the perioperative period to patients who meet inclusion/exclusion criteria. The informed consent document will be presented to the patient at this time for review. Contact information to the study's primary investigator and anesthesia associates will be provided on the informed consent documentation if the patient should require any further information about the study. If after reviewing the study details in the consent documentation, the patient is amenable to participating, they may provide consent by signing the consent form at the orthopedic surgeon's office free from coercion. Following enrollment in the study, patient data will be collected by the primary investigator's research team, stored securely, and all patient information and data will be de-identified prior to publication.
Risks/Benefits Anticipated risks of this study include the risks associated with the S-FICB procedure itself. These include infection, bleeding, injury to surrounding structures including nerves, and local anesthetic systemic toxicity which can occur if a large amount of local anesthetic is inadvertently injected intravascularly. This procedure is performed under sterile conditions, minimizing the risk of infection. In addition, patients who have local infection at the site of injection will be excluded as participants. The risks of major bleeding is rare for patients who do not have preexisting coagulopathies, and is low for patients who are on anticoagulation that has been discontinued an appropriate amount of time prior to surgery according to the American Society for Regional Anesthesia (ASRA) guidelines. Furthermore, the risk of nerve injury is greatly mitigated using ultrasound guidance in performing this type of nerve block where nerve tissue can be identified visually. Additionally, because this is a fascial plane block, the investigators do not aim to inject local anesthetic directly adjacent to nerve structures, minimizing risk of nerve injury or damage. The use of ultrasound guidance also mitigates the risk of local anesthetic systemic toxicity as blood vessels can be visualized and avoided. The practice of frequent aspiration during injection of local anesthetic also protects against this risk.
Another risk to participants of this study is the possible loss of confidentiality; however, the investigators have designed this study to include protocols for keeping patient information private. In addition, strict storage and de-identification of data will be used to protect patient information.
This study presents several possible benefits to participants and future patients who must undergo this surgery. It presents a potential avenue for decreasing opioid requirements in the perioperative period. Adverse events associated with opioids cause significant morbidity to the patient in the postoperative period. These include nausea, vomiting, sedation and dizziness that can lead to falls during attempted ambulation and inability to participate in physical therapy, and respiratory depression requiring intervention. All of these possible events can hinder recovery significantly and contribute to longer hospital lengths of stay.
Improved pain control overall is also a potential benefit to patients participating in this study. Decreasing the levels of pain experienced by patients is often instrumental in improving a patient's satisfaction with their surgery and in-hospital recovery. Decreased pain also makes it less challenging for a patient to participate fully in physical therapy, aiding in the recovery process after major orthopedic surgery.
If the results of this study support the use of the S-FICB showing improved outcomes for patients in the postoperative period, this peripheral nerve block can be more widely employed and incorporated as part of a multimodal perioperative opioid sparing pathway to improve outcomes for this patient population in the future.
The S-FICB is a relatively low-risk procedure, while the potential benefits to participants in this study, as well as future participants, is substantial.
Randomization On the day of surgery, an envelope containing the randomization code will be given to the regional team responsible for the study patient. Patients will be randomly allocated to receive S-FICB or standard of care using a 1:1 allocation ratio. --- BMI.--- A research associate who is not directly involved with the study procedures will maintain the randomization codes.
Allocation: Randomized
Intervention Model: Parallel Assignment
Treatment groups: Group A: Control Group - DAA THA under spinal anesthesia ( standard of care at Montefiore)
Group B: Intervention Group - DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
Blinding Procedures:
* On the day of surgery, a sealed envelope with group allocation (Group A- Control vs. Group B - Intervention) will be opened by a team member not involved with data collection.
* For patients allocated to Group B - Intervention: A regional anesthesia block team consisting of a regional anesthesiologist, regional fellow, and resident will carry out the S-FICB in the preoperative area prior to surgery
* A separate anesthesia team consisting of an anesthesiologist and certified nurse anesthetist will be responsible for the spinal anesthetic and monitored anesthesia care for both groups in the operating room
* A separate acute pain service team will follow the patients in both groups on postoperative day 1 and evaluate sensory and motor distribution of LFCN, FN, and ON for both groups
* A research assistant blinded to the allocation of both groups will collect data from the EMR for analysis. In addition, a research assistant blinded to the allocation of both groups will call patients via telephone 24 hours post-discharge for a patient satisfaction survey.
Hypothesis: The supra-inguinal fascia iliaca compartment block will decrease 24 hours post-surgery opioid requirements in patients undergoing elective direct anterior approach to total hip arthroplasty.
Target Population: Patients undergoing primary elective total hip arthroplasty under direct anterior surgical approach
Recruitment methods: Participants who meet the inclusion/exclusion criteria for the study will be approached to participate in the study at the preoperative visit at the Orthopedic Surgeon's Office. Informed consent for participation in the study will be obtained during the preoperative visit.
The planned interventions and their timing:
* On the day of surgery, patients who have been randomized to Group B - Intervention will receive a preoperative S-FICB using 35 ml of 0.5% ropivacaine (max dose of 3mg/kg) under ultrasound guidance by the regional anesthesia block team once the patient has been marked by the surgeon
* The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. For those patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory and motor distribution of LFCN, FN, and ON will be assessed by the regional anesthesia block team prior to going to the operating room.
* All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory and motor distribution of LFCN, FN, and ON and adjustment of pain medication regimens
* All patients will receive a telephone call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
* Postoperatively all patients will be placed on the following pain regimen:
* All patients will be started on a Hydromorphone intravenous patient-controlled analgesia (PCA) for 24 hours, with starting parameters: 0.2mg q10 min bolus dosing without a basal rate.
* A standardized regimen of non-opioid adjuvants will include: Acetaminophen 975mg po q8h, Pregabalin 50mg po BID, Ketorolac 15mg q8h IV x 24 hours followed by Celebrex 200mg po BID.
* After the first 24 hours, patients will be transitioned off the hydromorphone PCA with oxycodone 5mg PO q4h prn for moderate pain and 10mg PO q4h prn for severe pain, hydromorphone 0.2mg IV q4h prn for breakthrough pain. These doses may be increased or decreased thereafter at the discretion of the acute pain service team based on patient evaluation and reported pain scores.
Study Population
A. Patients undergoing elective primary total hip arthroplasty under direct anterior surgical approach with neuraxial anesthesia
Participant Recruitment
Participants will be recruited during their preoperative visit to the office of the orthopedic surgery team performing the patient's surgery. At this visit, where the patient will be consented for the surgery itself, the orthopedic surgery team will present the opportunity to participate in this study during the perioperative period to patients who meet inclusion/exclusion criteria. The informed consent document will be presented to the patient at this time for review. Contact information to the study's primary investigator and anesthesia associates will be provided on the informed consent documentation if the patient should require any further information about the study. If after reviewing the study details in the consent documentation, the patient is amenable to participating, they may provide consent by signing the consent form at the orthopedic surgeon's office free from coercion. Following enrollment in the study, patient data will be collected by the primary investigator's research team, stored securely, and all patient information and data will be de-identified prior to publication.
Risks/Benefits Anticipated risks of this study include the risks associated with the S-FICB procedure itself. These include infection, bleeding, injury to surrounding structures including nerves, and local anesthetic systemic toxicity which can occur if a large amount of local anesthetic is inadvertently injected intravascularly. This procedure is performed under sterile conditions, minimizing the risk of infection. In addition, patients who have local infection at the site of injection will be excluded as participants. The risks of major bleeding is rare for patients who do not have preexisting coagulopathies, and is low for patients who are on anticoagulation that has been discontinued an appropriate amount of time prior to surgery according to the American Society for Regional Anesthesia (ASRA) guidelines. Furthermore, the risk of nerve injury is greatly mitigated using ultrasound guidance in performing this type of nerve block where nerve tissue can be identified visually. Additionally, because this is a fascial plane block, the investigators do not aim to inject local anesthetic directly adjacent to nerve structures, minimizing risk of nerve injury or damage. The use of ultrasound guidance also mitigates the risk of local anesthetic systemic toxicity as blood vessels can be visualized and avoided. The practice of frequent aspiration during injection of local anesthetic also protects against this risk.
Another risk to participants of this study is the possible loss of confidentiality; however, the investigators have designed this study to include protocols for keeping patient information private. In addition, strict storage and de-identification of data will be used to protect patient information.
This study presents several possible benefits to participants and future patients who must undergo this surgery. It presents a potential avenue for decreasing opioid requirements in the perioperative period. Adverse events associated with opioids cause significant morbidity to the patient in the postoperative period. These include nausea, vomiting, sedation and dizziness that can lead to falls during attempted ambulation and inability to participate in physical therapy, and respiratory depression requiring intervention. All of these possible events can hinder recovery significantly and contribute to longer hospital lengths of stay.
Improved pain control overall is also a potential benefit to patients participating in this study. Decreasing the levels of pain experienced by patients is often instrumental in improving a patient's satisfaction with their surgery and in-hospital recovery. Decreased pain also makes it less challenging for a patient to participate fully in physical therapy, aiding in the recovery process after major orthopedic surgery.
If the results of this study support the use of the S-FICB showing improved outcomes for patients in the postoperative period, this peripheral nerve block can be more widely employed and incorporated as part of a multimodal perioperative opioid sparing pathway to improve outcomes for this patient population in the future.
The S-FICB is a relatively low-risk procedure, while the potential benefits to participants in this study, as well as future participants, is substantial.
Randomization On the day of surgery, an envelope containing the randomization code will be given to the regional team responsible for the study patient. Patients will be randomly allocated to receive S-FICB or standard of care using a 1:1 allocation ratio. --- BMI.--- A research associate who is not directly involved with the study procedures will maintain the randomization codes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Anesthesia, Local
Block
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Caregivers
Outcome Assessors
On the day of surgery, a sealed envelope with group allocation (Group A- Control vs. Group B - Intervention) will be opened by a team member not involved with data collection.
A separate anesthesia team consisting of an anesthesiologist and certified nurse anesthetist will be responsible for the spinal anesthetic and monitored anesthesia care for both groups in the operating room A separate acute pain service team will follow the patients in both groups on postoperative day 1 and evaluate sensory and motor distribution of LFCN, FN, and ON for both groups A research assistant blinded to the allocation of both groups will collect data from the EMR for analysis. In addition, a research assistant blinded to the allocation of both groups will call patients via telephone 24 hours post-discharge for a patient satisfaction survey.
A separate anesthesia team consisting of an anesthesiologist and certified nurse anesthetist will be responsible for the spinal anesthetic and monitored anesthesia care for both groups in the operating room A separate acute pain service team will follow the patients in both groups on postoperative day 1 and evaluate sensory and motor distribution of LFCN, FN, and ON for both groups A research assistant blinded to the allocation of both groups will collect data from the EMR for analysis. In addition, a research assistant blinded to the allocation of both groups will call patients via telephone 24 hours post-discharge for a patient satisfaction survey.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
DAA THA under spinal anesthesia ( standard of care at Montefiore)
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
Intervention Group
DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
Group Type
ACTIVE_COMPARATOR
Suprainguinal fascia ilica block
Intervention Type
PROCEDURE
Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Suprainguinal fascia ilica block
Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
Intervention Type
PROCEDURE
Placebo
The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing primary elective total hip arthroplasty under direct anterior surgical approach
* ASA Class I-III
* Age \> 18 years old
* ASA Class I-III
* Age \> 18 years old
Exclusion Criteria
Patient refusal
* Inability to understand and sign an informed consent
* Infection at the injection site
* Allergy or hypersensitivity to ropivacaine or other amide local anesthetics
* Contraindication or patient refusal to get spinal anesthesia
* Thrombocytopenia (Platelets \< 100, 000)
* Coagulopathy (INR \> 1.4)
* Use of anticoagulant drugs that have not been discontinued in an appropriate amount of time - according to American Society of Regional Anesthesia guidelines, prior to surgery
* End-Stage Renal Disease
* ASA Class IV-V
* Patients on chronic opioid therapy on most days for \> 3 months \[19\].
* BMI\>40
* Inability to understand and sign an informed consent
* Infection at the injection site
* Allergy or hypersensitivity to ropivacaine or other amide local anesthetics
* Contraindication or patient refusal to get spinal anesthesia
* Thrombocytopenia (Platelets \< 100, 000)
* Coagulopathy (INR \> 1.4)
* Use of anticoagulant drugs that have not been discontinued in an appropriate amount of time - according to American Society of Regional Anesthesia guidelines, prior to surgery
* End-Stage Renal Disease
* ASA Class IV-V
* Patients on chronic opioid therapy on most days for \> 3 months \[19\].
* BMI\>40
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Montefiore Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sofia steinberg, DO
Role: PRINCIPAL_INVESTIGATOR
Montefiore Medical Center
References
Explore related publications, articles, or registry entries linked to this study.
Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage. 2020 Mar;28(3):242-248. doi: 10.1016/j.joca.2020.01.002. Epub 2020 Jan 13.
Reference Type
BACKGROUND
Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5. doi: 10.2106/JBJS.F.00222.
Reference Type
BACKGROUND
Zhang D, Pan L, Maimaitijuma T, Liu H, Wu H. Imaging Analysis of Prosthesis Angle after Hip Replacement with Direct Anterior Approach in Lateral Position. J Healthc Eng. 2021 Feb 17;2021:5540834. doi: 10.1155/2021/5540834. eCollection 2021.
Reference Type
BACKGROUND
Galakatos GR. Direct Anterior Total Hip Arthroplasty. Mo Med. 2018 Nov-Dec;115(6):537-541.
Reference Type
BACKGROUND
Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S, Manworren R, McCarberg B, Montgomery R, Murphy J, Perkal MF, Suresh S, Sluka K, Strassels S, Thirlby R, Viscusi E, Walco GA, Warner L, Weisman SJ, Wu CL. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016 Feb;17(2):131-57. doi: 10.1016/j.jpain.2015.12.008.
Reference Type
BACKGROUND
Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg. 2017 Nov;125(5):1749-1760. doi: 10.1213/ANE.0000000000002497.
Reference Type
BACKGROUND
Bugada D, Bellini V, Lorini LF, Mariano ER. Update on Selective Regional Analgesia for Hip Surgery Patients. Anesthesiol Clin. 2018 Sep;36(3):403-415. doi: 10.1016/j.anclin.2018.04.001. Epub 2018 Jul 11.
Reference Type
BACKGROUND
Xia Q, Ding W, Lin C, Xia J, Xu Y, Jia M. Postoperative pain treatment with transmuscular quadratus lumborum block and fascia iliaca compartment block in patients undergoing total hip arthroplasty: a randomized controlled trial. BMC Anesthesiol. 2021 Jul 10;21(1):188. doi: 10.1186/s12871-021-01413-7.
Reference Type
BACKGROUND
Nassar H, Hasanin A, Sewilam M, Ahmed H, Abo-Elsoud M, Taalab O, Rady A, Zoheir HA. Transmuscular Quadratus Lumborum Block versus Suprainguinal Fascia Iliaca Block for Hip Arthroplasty: A Randomized, Controlled Pilot Study. Local Reg Anesth. 2021 Apr 20;14:67-74. doi: 10.2147/LRA.S308964. eCollection 2021.
Reference Type
BACKGROUND
Desmet M, Balocco AL, Van Belleghem V. Fascia iliaca compartment blocks: Different techniques and review of the literature. Best Pract Res Clin Anaesthesiol. 2019 Mar;33(1):57-66. doi: 10.1016/j.bpa.2019.03.004. Epub 2019 Apr 17.
Reference Type
BACKGROUND
O'Reilly N, Desmet M, Kearns R. Fascia iliaca compartment block. BJA Educ. 2019 Jun;19(6):191-197. doi: 10.1016/j.bjae.2019.03.001. Epub 2019 Apr 24. No abstract available.
Reference Type
BACKGROUND
Dalens B, Vanneuville G, Tanguy A. Comparison of the fascia iliaca compartment block with the 3-in-1 block in children. Anesth Analg. 1989 Dec;69(6):705-13.
Reference Type
BACKGROUND
Dolan J, Williams A, Murney E, Smith M, Kenny GN. Ultrasound guided fascia iliaca block: a comparison with the loss of resistance technique. Reg Anesth Pain Med. 2008 Nov-Dec;33(6):526-31. doi: 10.1016/j.rapm.2008.03.008.
Reference Type
BACKGROUND
Hebbard P, Ivanusic J, Sha S. Ultrasound-guided supra-inguinal fascia iliaca block: a cadaveric evaluation of a novel approach. Anaesthesia. 2011 Apr;66(4):300-5. doi: 10.1111/j.1365-2044.2011.06628.x. Epub 2011 Feb 24.
Reference Type
BACKGROUND
Vermeylen K, Desmet M, Leunen I, Soetens F, Neyrinck A, Carens D, Caerts B, Seynaeve P, Hadzic A, Van de Velde M. Supra-inguinal injection for fascia iliaca compartment block results in more consistent spread towards the lumbar plexus than an infra-inguinal injection: a volunteer study. Reg Anesth Pain Med. 2019 Feb 22:rapm-2018-100092. doi: 10.1136/rapm-2018-100092. Online ahead of print.
Reference Type
BACKGROUND
Zhang XY, Ma JB. The efficacy of fascia iliaca compartment block for pain control after total hip arthroplasty: a meta-analysis. J Orthop Surg Res. 2019 Jan 25;14(1):33. doi: 10.1186/s13018-018-1053-1.
Reference Type
BACKGROUND
Desmet M, Vermeylen K, Van Herreweghe I, Carlier L, Soetens F, Lambrecht S, Croes K, Pottel H, Van de Velde M. A Longitudinal Supra-Inguinal Fascia Iliaca Compartment Block Reduces Morphine Consumption After Total Hip Arthroplasty. Reg Anesth Pain Med. 2017 May/Jun;42(3):327-333. doi: 10.1097/AAP.0000000000000543.
Reference Type
BACKGROUND
Flevas DA, Tsantes AG, Mavrogenis AF. Direct Anterior Approach Total Hip Arthroplasty Revisited. JBJS Rev. 2020 Apr;8(4):e0144. doi: 10.2106/JBJS.RVW.19.00144.
Reference Type
BACKGROUND
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.
Reference Type
BACKGROUND
Memtsoudis SG, Poeran J, Cozowicz C, Zubizarreta N, Ozbek U, Mazumdar M. The impact of peripheral nerve blocks on perioperative outcome in hip and knee arthroplasty-a population-based study. Pain. 2016 Oct;157(10):2341-2349. doi: 10.1097/j.pain.0000000000000654.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-13705
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Suprainguinal Fascia Iliaca Block Versus PENG Block for Hip Arthroplasty Analgesia
NCT04402450
COMPLETED
NA
Lumbar Plexus and Suprainguinal Fascia Iliaca Blocks For Total Hip Replacement
NCT03744065
COMPLETED
NA
Lateral Cutaneous Nerve and PENG Blocks Versus Suprainguinal Fascia Iliaca Block in Post-op Analgesia of Hip Fractures
NCT05749367
UNKNOWN
NA
The Pericapsular Nerve Block in Total Hip Arthroplasty
NCT04729686
RECRUITING
PHASE4
Fascia Iliaca Compartment Blocks for Pain Control in Hip Fractures
NCT04086914
WITHDRAWN
EARLY_PHASE1
Fascia Iliaca Compartment Block Versus Quadratus Lumborum Block in Total Hip Arthroplasty
NCT05228028
COMPLETED
NA
PENG Block vs Supra-inguinal Fascia Iliaca Compartment Block for Postoperative Opioids Consumption and Early Motor Recovery After THA: a Randomized Controlled Non-inferiority Clinical Trial.
NCT04690023
UNKNOWN
PHASE4
Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy
NCT02717728
WITHDRAWN
PHASE3
Does Adding Posterior Block to SFIB Increase the Quality of Analgesia in Hip Fractures?
NCT06839742
COMPLETED
NA
Ultrasound-guided Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Total Hip Arthroplasty
NCT03069183
COMPLETED
PHASE2/PHASE3
Efficacy of Fascia Iliaca Block Versus Intraoperative Nerve Infiltration During Anterior Hip Replacement Surgery
NCT01693900
COMPLETED
NA
Ultrasound Guided Fascia Iliaca Block for Pain Control After Elective Hip Replacement Surgery
NCT02108847
COMPLETED
NA
An Iliopsoas Plane Block After Total Hip Arthroplasty
NCT05212038
COMPLETED
NA
The Analgesic Effect of Pericapsular Nerve Group Block With Lateral Femoral Cutaneous Nerve Block and Pericapsular Nerve Group Block With Supra-inguinal Fascia Iliaca Block in Hip Hemiarthroplasty
NCT06577103
COMPLETED
NA
Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement
NCT02161484
TERMINATED
NA
Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery
NCT02289937
COMPLETED
PHASE4
MED90 of Ropivacaine for Peripheral Nerve Block on Posture-evoked Pain in Spinal Anesthesia Positioning
NCT04705974
UNKNOWN
NA
Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia
NCT06818396
RECRUITING
NA
Comparative Study Between Pericapsular Nerve Group Block (PENG) Versus Suprainguinal Fascia Iliaca Compartment Block (SIFIC) in Perioperative Hip Surgery
NCT07232173
COMPLETED
NA
Comparing Postoperative Pain After Pericapsular Nerve Block and Fascia Iliaca Block in Total Hip Arthroplasty
NCT06003738
UNKNOWN
NA
Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty
NCT06982625
RECRUITING
NA
Pericapsular Nerve Group Block vs Supra Inguinal Fascia Iliaca Compartment Block
NCT06321718
COMPLETED
NA
Adductor Canal Vs Adductor Canal Plus SPANK Block for Postoperative Pain in Knee Arthroplasty Surgery
NCT04290442
WITHDRAWN
PHASE4
CMP vs Fascia Iliaca Block
NCT04426058
UNKNOWN
NA
Suprainguinal Fascia Iliaca Block in Knee Arthroplasty
NCT06386575
COMPLETED
NA